Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R. Flaherty, Kevin K. Brown, Kay Tetzlaff et al.|New England Journal of Medicine|2019Cited by 2.3k
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Kevin R. Flaherty et al.|The Lancet Respiratory Medicine|2020Cited by 558
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Marlies Wijsenbeek, Arata Azuma et al.|New England Journal of Medicine|2025Cited by 159
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M. Maher, Fernando J. Martínez, Shervin Assassi et al.|New England Journal of Medicine|2025Cited by 134